Jul 29, 2026 05:15PM
Jul 9, 2026 09:37AM
May 18, 2026 04:46PM
Apr 30, 2026 06:22AM
Apr 30, 2026 06:00AM
Feb 5, 2026 07:24AM
Nov 20, 2025 07:45AM OS Therapies (OSTX) plans to spin off animal health unit as public company
Nov 17, 2025 06:26AM
Aug 4, 2025 04:33PM
Jul 3, 2025 07:41AM
Jun 30, 2025 06:02AM
Jun 24, 2025 07:41AM
Jun 10, 2025 07:40AM
Jun 6, 2025 07:31AM OS Therapies (OSTX) Submits Request for Regenerative Medicine Advanced Therapy Designation to FDA for OST-HER2
May 16, 2025 04:34PM
May 7, 2025 08:45AM
Apr 22, 2025 07:41AM
Apr 22, 2025 07:34AM
Apr 9, 2025 07:40AM
Mar 31, 2025 07:40AM
Feb 24, 2025 07:25AM OS Therapies (OSTX) Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Feb 20, 2025 05:54AM
Feb 14, 2025 07:36AM
Feb 4, 2025 07:33AM
Jan 15, 2025 07:45AM
Dec 31, 2024 03:38PM
Dec 26, 2024 10:03AM
Dec 24, 2024 09:32AM OS Therapies (OSTX) Prices 1.5M Unit Offering at $4/unit
Oct 28, 2024 04:44PM
Sep 13, 2024 08:09AM
Sep 3, 2024 07:17AM
Aug 29, 2024 07:53AM
Aug 22, 2024 01:01PM
Aug 2, 2024 08:56AM
Jul 24, 2024 10:50AM OS Therapies (OSTX) Reports Positive Safety Data from Phase 1 Clinical Trial of OST-HER2

434,866 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All